Drug Trial Radar · NCT07919899
Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
May 2, 2028
Study completion Jul 25, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open label, randomized, parallel-group, 2-arm study. The purpose of this study is to measure PK, immunogenicity, safety and, tolerability of dupilumab hyaluronidase coformulation compared with dupilumab approved formulation in male or female participants with moderate-to-severe atopic dermatitis (AD) aged ≥12 years of age. Study details as follows: * The study duration includes screening period up to 4 weeks + treatment period of 20 weeks (± 3 days) and follow-up of 12 weeks (± 7 days). * The number of on-site visits will be 10 and one phone contact will be scheduled (during the follow-up period).
Conditions
- Dermatitis Atopic
Interventions
Dupilumab coformulated with berahyaluronidase alfaDrug
Pharmaceutical form: solution for injection Route of administration: SC injection
DupilumabDrug
Pharmaceutical form: solution for injection Route of administration: SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ctrough,ss at Week 20Time frame: Week 20
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.